Search
Search Results
##search.searchResults.foundPlural##
-
ESCHERICHIA COLI: AN IMPORTANT PATHOGEN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
2305PDF: 755HTML: 2145Untitled: 250Untitled: 172Untitled: 204Untitled: 177Untitled: 195Untitled: 202Untitled: 207 -
CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES
3322PDF: 967HTML: 3203 -
IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY COVID-19 and hematologic malignancy
1902PDF: 836HTML: 230 -
THE ROLE OF WHITE BLOOD CELL COUNT IN PERIANAL PATHOLOGIES: A RETROSPECTIVE ANALYSIS OF HEMATOLOGIC MALIGNANCIES Role of white blood cell count in perianal pathologies
4080PDF: 2012HTML: 275 -
EVALUATION OF USING EMPIRIC GLYCOPEPTIDES IN ACCORDANCE WITH THE IDSA GUIDELINE IN HEMATOLOGIC MALIGNANCY PATIENTS WITH FEBRILE NEUTROPENIA Empiric glycopeptide use in neutropenic fever
1599PDF: 1148HTML: 264 -
NUTRITIONALLY VARIANT STREPTOCOCCI BACTEREMIA IN CANCER PATIENTS: A RETROSPECTIVE STUDY, 1999-2014
2235PDF: 1038HTML: 4096Cover Letter: 242Figure 1: 256Figure 2: 249Table 1: 230 -
SARS-CoV-2 INFECTED PATIENTS: FROM A HEMATOLOGIST PERSPECTIVE COVID-19 and Hematology
1376PDF: 998HTML: 441 -
DIAGNOSTIC VALUE OF BRONCHOALVEOLAR LAVAGE IN LEUKEMIC AND BONE MARROW TRANSPLANT PATIENTS: THE IMPACT OF ANTIMICROBIAL THERAPY
2031PDF: 848HTML: 2213Table 1: 204Table 2: 219Table 3: 217Table 4: 219Table 5: 215Tble 6: 209Cover Letter: 229Greene Tab.7: 228 -
ANTIFUNGAL THERAPY IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
4863PDF: 1603HTML: 2265Untitled: 252Untitled: 266Untitled: 286Untitled: 236Untitled: 253 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2597PDF: 1745HTML: 543 -
EPIDEMIOLOGY OF INVASIVE FUNGAL INFECTIONS IN THE MEDITERRANEAN AREA
2326PDF: 1023HTML: 4983 -
INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
3562PDF: 1430HTML: 2721 -
THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS
2749PDF: 791HTML: 2324 -
TUBERCULOSIS IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES
3430PDF: 1286HTML: 8394 -
Bordetella Bronchiseptica in the Immunosuppressed Population – A Case Series and Review.
2566PDF: 1358HTML: 1827CoverLetter: 204 -
COVID-19 IN CHILDREN AND ADOLESCENT: CHARACTERISTICS AND SPECIFICITIES IN IMMUNOCOMPETENT AND ONCOHEMATOLOGICAL PATIENTS COVID-19 IN CHILDREN AND ADOLESCENT.
2657PDF: 977HTML: 594 -
ASSESSMENT OF CONGENITAL NEUTROPENIA IN CHILDREN: COMMON CLINICAL SCENERIES AND CLUES FOR MANAGEMENT Assessment of congenital neutropenia in children
2511PDF: 1222HTML: 1068 -
ZYGOMYCOSIS IN IMMUNOCOMPROMISED NON-HAEMATOLOGICAL PATIENTS
2991PDF: 1000HTML: 7496 -
-
Evaluating the use of meropenem in hematologic patients with febrile neutropenia A retrospective observational single-cohort study
1284PDF: 504HTML: 153 -
NF- ?B Essential Modulator Deficiency Leading to Disseminated Cutaneous Atypical Mycobacteria
1923PDF: 1147HTML: 10754Untitled: 213 -
Bilateral Pleural Effusions due to Pulmonary Amyloidosis as the Presenting Manifestation of Multiple Myeloma
1393PDF: 796HTML: 4412Figure 1: 179Untitled: 160Untitled: 213 -
THE IMPORTANCE OF TARGETED NEXT-GENERATION SEQUENCING USAGE IN CYTOGENETICALLY NORMAL MYELOID MALIGNANCIES Targeted next-generation sequencing usage in cytogenetically normal myeloid malignancies
2220PDF: 600HTML: 368 -
OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
2337PDF: 1091HTML: 2026Characteristic of study group: 220 -
EBV-RELATED LYMPHOPROLIFERATIVE DISEASES: A REVIEW IN LIGHT OF NEW CLASSIFICATIONS EBV-RELATED LYMPHOPROLIFERATIVE DISEASES
4620PDF: 1786HTML: 1230 -
INCREASE IN CANDIDA PARAPSILOSIS CANDIDEMIA IN CANCER PATIENTS
1870PDF: 1107HTML: 303 -
Ceftolozane-Tazobatam for febrile neutropenia treatment in hematologic malignancy patients colonized by multi-resistant Enterobacteriaceae: preliminary results from a prospective cohort study Ceftolozane-Tazobatam for febrile neutropenia
7963PDF: 751HTML: 255 -
RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES
3919PDF: 1722HTML: 11837Figures Haase: 237 -
THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition
1482PDF: 963HTML: 253







